Form D · Biotechnology

eGenesis, Inc.

Cambridge, MA · CIK 0001682809

Offering snapshot reported Feb 27, 2024 · SEC filing

Reported sold
$25.4M
Offering amount: $28.7M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 13, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 27, 2024Initial$25,419,995No comparison11SEC filing
Mar 10, 2021Initial$124,999,955No comparison43SEC filing
Nov 14, 2019Initial$100,000,000No comparison20SEC filing
Mar 23, 2017Initial$12,618,399No comparison12SEC filing
Aug 23, 2016Initial$2,000,000No comparison2SEC filing

Offering details

Securities
Debt, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-506139

Source: Form D, filed Feb 27, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jennifer Bergheiser Executive
George M. Church Director
Isaac Ciechanover Director
Michael Curtis Director, Executive
Juergen Eckhardt Director
Kenneth Fan Executive
Kathleen Fanning Director
Stephen Gillis Director
Steven Gillis Director
Peter Hanson Executive
Lucio Iannone Director
Ariel Jasie Executive
Rahul Kakkar Director
Geoff Mac Kay Executive
Bob More Director
Boris Nikolic Director
Mark Pruzanski Director
Sarah Schlesinger Director
Paul Sekhri Director
Brad Smith Director
Sapna Srivastava Executive
Julie Sunderland Director
Albert Wiegman Director
Luhan Yang Director, Executive, Promoter

Issuer details

Industry: Biotechnology (See others in industry)

Address:
101 Cambridgepark Dr., Suite 200
Cambridge, MA, 02140